Advanced BioScience Laboratories (ABL), a global CDMO and CRO to the U.S. Government and biopharmaceutical industry, is one of three contractors awarded an Indefinite Delivery, Indefinite Quantity (IDIQ)  contract for manufacturing and nonclinical studies support for the development of biologics for neurological-related disorders by the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) of the U.S. Department of Health and Human Services (HHS), contract number 75N95022D00023.
 
The eight-year, multiple-award-IDIQ contract has a total potential funding value of $149.2 million. ABL will provide NINDS cGMP manufacturing and GLP preclinical services to support translational development of therapeutic biologics of various modalities for NIH’s drug discovery and development programs. This contract supports the NIH Biologics development projects for the NIH Blueprint Neurotherapeutics Network Biologics (BPN-Biologics) program, the NINDS Ultra-Rare Gene Therapy (URGenT) program, the Helping to End Addiction Long-term Pain Therapeutics Development Program (HEAL-PTDP), and other extramural or intramural NIH drug discovery and development programs.  
 
ABL’s portfolio of services includes feasibility studies, process and assay development, cGMP manufacturing, IND-enabling GLP safety, pharmacokinetic and efficacy studies, stability studies, and product release testing.  These services are provided either at ABL facilities or at one of the 42 companies that formed the ABL Collaboration to support this contract.
 
“We look forward to continuing to serve the mission of the NIH through this contract with NINDS and in support of the most innovative investigators in the field who are developing cutting-edge products that prevent, treat, and cure neurological disorders, stroke, and ultra-rare genetic disease,” said Marykay Marchigiani, COO of ABL.